Keith Regnante Keros Therapeutics, Inc. (KROS) insider trading activity

Keith Regnante is CHIEF FINANCIAL OFFICER of Keros Therapeutics, Inc.. Currently has a direct ownership of 44,000 shares of KROS, which is worth approximately $484,440. The most recent transaction as insider was on Feb 18, 2025, when has been sold 44,000 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 44K

Infinity% 3M change

Infinity% 12M change

Total Value Held $484,440

Keith Regnante Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 18 2025	BUY Grant, award, or other acquisition	-	44,000 Added 50.0%	44,000 Common Stock
Nov 04 2023	SELL Open market or private sale	$1,811,600 $45.29 p/Share	40,000 Reduced 100.0%	0 Common Stock
Nov 04 2023	BUY Exercise of conversion of derivative security	$640,000 $16.0 p/Share	40,000 Added 50.0%	40,000 Common Stock
Jun 09 2023	SELL Open market or private sale	$925,000 $46.25 p/Share	20,000 Reduced 100.0%	0 Common Stock
Jun 09 2023	BUY Exercise of conversion of derivative security	$320,000 $16.0 p/Share	20,000 Added 50.0%	20,000 Common Stock
Jun 08 2023	SELL Open market or private sale	$963,199 $48.16 p/Share	20,000 Reduced 100.0%	0 Common Stock
Jun 08 2023	BUY Exercise of conversion of derivative security	$320,000 $16.0 p/Share	20,000 Added 50.0%	20,000 Common Stock

Keith Regnante

CHIEF FINANCIAL OFFICER

Lexington, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KROS shares.

Notify only if

Value

Insider Trading

Get notified when an Keros Therapeutics, Inc. insider buys or sells KROS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Keros Therapeutics, Inc.

Track Activities on KROS

Account